Internal Medicine, Hematology & Oncology · Elmhurst, NY
NPI
1124330675
Since 2010
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
8806 55th Ave
Elmhurst, NY, 11373
Phone (855) 528-7322
Groups this clinician bills Medicare through
Medicare paid, 2024
$826K
67,483 services
Medicare patients, 2024
496
Average age 76
Drug cost, 2024
$4.4M
741 prescriptions
Company payments, 2025
$39.94
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Byung M Kim was code J1439 (injection, ferric carboxymaltose, 1 mg), 25,500 times for 24 patients. In total Byung M Kim billed 67,483 services in 156 codes, and Medicare paid $826K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-04-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 25,500 | 24 | $0.87 | $22K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 6,500 | 12 | $2.19 | $14K |
| 88185 Surgical Pathology Examination | Office | 1,019 | 44 | $22.09 | $23K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 818 | 38 | $0.09 | $71.83 |
| 36415 Venipuncture Blood Collection | Office | 622 | 236 | $8.65 | $5,380 |
| 85025 Blood Count | Office | 563 | 224 | $7.61 | $4,284 |
| 99233 Hospital E&M - Subsequent | Facility | 561 | 234 | $102.33 | $57K |
| 80053 Clinical Chemistry | Office | 428 | 194 | $10.35 | $4,430 |
| 83615 Clinical Chemistry | Office | 340 | 150 | $5.92 | $2,013 |
| 84100 Clinical Chemistry | Office | 212 | 123 | $4.65 | $986 |
| 83735 Clinical Chemistry | Office | 207 | 116 | $6.57 | $1,360 |
| 84550 Clinical Chemistry | Office | 196 | 108 | $4.43 | $868 |
| 82784 Immunoassay | Office | 195 | 51 | $9.11 | $1,777 |
| 83540 Clinical Chemistry | Office | 184 | 106 | $6.34 | $1,167 |
| 82728 Clinical Chemistry | Office | 184 | 106 | $13.36 | $2,458 |
By year: 2022 $95K for 969 services; 2023 $378K for 26,437 services; 2024 $826K for 67,483 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 88185 Surgical Pathology Examination | 1,019 | 44 | $22.09 | $23K |
| 36415 Venipuncture Blood Collection | 622 | 236 | $8.65 | $5,380 |
| 85025 Blood Count | 563 | 224 | $7.61 | $4,284 |
| 80053 Clinical Chemistry | 428 | 194 | $10.35 | $4,430 |
| 83615 Clinical Chemistry | 340 | 150 | $5.92 | $2,013 |
| 84100 Clinical Chemistry | 212 | 123 | $4.65 | $986 |
| 83735 Clinical Chemistry | 207 | 116 | $6.57 | $1,360 |
| 84550 Clinical Chemistry | 196 | 108 | $4.43 | $868 |
| 82784 Immunoassay | 195 | 51 | $9.11 | $1,777 |
| 83540 Clinical Chemistry | 184 | 106 | $6.34 | $1,167 |
Medicare prescription drug claims, 2024
In 2024, the drug Byung M Kim prescribed most often to Medicare patients was Akynzeo (Fosnetupitant/Palonosetron), with 54 prescriptions and refills. In total Byung M Kim wrote 741 Medicare prescriptions that cost $4.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Akynzeo Fosnetupitant/Palonosetron | 54 | 54 | 15 | $71K |
| Aranesp Darbepoetin Alfa In Polysorbat | 40 | 40 | 13 | $107K |
| Anastrozole Generic | 36 | 74 | 15 | $537 |
| Revlimid Lenalidomide | 34 | 34 | Under 11 | $649K |
| Eliquis Apixaban | 27 | 32 | Under 11 | $18K |
| Prednisone Generic | 26 | 32 | Under 11 | $89.75 |
| Mvasi Bevacizumab-Awwb | 25 | 25 | Under 11 | $163K |
| Neulasta Onpro Pegfilgrastim | 24 | 24 | Under 11 | $150K |
| Abiraterone Acetate Generic | 22 | 22 | Under 11 | $24K |
| Xgeva Denosumab | 22 | 22 | Under 11 | $69K |
| Darzalex Faspro Daratumumab-Hyaluronidase-Fihj | 20 | 20 | Under 11 | $320K |
| Bortezomib Generic | 19 | 19 | Under 11 | $24K |
| Brukinsa Zanubrutinib | 19 | 19 | Under 11 | $259K |
| Procrit Epoetin Alfa | 19 | 19 | Under 11 | $31K |
| Imfinzi Durvalumab | 18 | 18 | Under 11 | $224K |
Brand drugs: 490 claims; generic drugs: 251 claims; opioid claims: 14.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Byung M Kim $39.94 ($39.94 in general payments such as food, travel and fees) from 1 company. The largest payer was Boston Scientific Corporation with $39.94.
| Company | Payments | Amount |
|---|---|---|
| Boston Scientific Corporation BSX | 1 | $39.94 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.